文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Serotonin pharmacology in the gastrointestinal tract: a review.

作者信息

Beattie D T, Smith J A M

机构信息

Pharmacology Department, Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):181-203. doi: 10.1007/s00210-008-0276-9. Epub 2008 Apr 9.


DOI:10.1007/s00210-008-0276-9
PMID:18398601
Abstract

Serotonin (5-hydroxytryptamine or 5-HT) plays a critical physiological role in the regulation of gastrointestinal (GI) function. 5-HT dysfunction may also be involved in the pathophysiology of a number of functional GI disorders, such as chronic constipation, irritable bowel syndrome and functional dyspepsia. This article describes the role of 5-HT in the enteric nervous system (ENS) of the mammalian GI tract and the receptors with which it interacts. Existing serotonergic therapies that have proven effective in the treatment of GI functional disorders and the potential of drugs currently in development are also highlighted. Advances in our understanding of the physiological and pathophysiological roles of 5-HT in the ENS and the identification of selective receptor ligands bodes well for the future development of more efficacious therapies for patients with functional GI disorders.

摘要

相似文献

[1]
Serotonin pharmacology in the gastrointestinal tract: a review.

Naunyn Schmiedebergs Arch Pharmacol. 2008-5

[2]
Role of serotonin in gastrointestinal physiology and pathology.

Minerva Endocrinol. 2011-12

[3]
Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.

Aliment Pharmacol Ther. 2004-11

[4]
Serotonin and the GI tract.

Curr Gastroenterol Rep. 2009-10

[5]
Novel aspects of enteric serotonergic signaling in health and brain-gut disease.

Am J Physiol Gastrointest Liver Physiol. 2019-11-4

[6]
Drugs acting on serotonin receptors for the treatment of functional GI disorders.

Dig Dis. 2006

[7]
5-HT in the enteric nervous system: gut function and neuropharmacology.

Trends Neurosci. 2007-1

[8]
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.

Drugs. 2001

[9]
Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.

Handb Exp Pharmacol. 2017

[10]
The Role of Serotonin Neurotransmission in Gastrointestinal Tract and Pharmacotherapy.

Molecules. 2022-3-3

引用本文的文献

[1]
Cannabidiol (CBD) and Colorectal Tumorigenesis: Potential Dual Modulatory Roles via the Serotonergic Pathway.

Curr Oncol. 2025-6-26

[2]
Acetaminophen, a new tool for the refinement of the experimental infection of toxoplasmosis in mice.

Sci Rep. 2025-7-1

[3]
Wuzhuyu Decoction Relieves Chronic Migraine by Regulating 5-HT1A and 3A Receptors-Mediated CREB Signaling Pathway in Brain and Intestine.

Pharmaceuticals (Basel). 2025-3-18

[4]
Serotoninergic Mechanisms of Action in the Relaxant Properties of Saccharomyces boulardii CNCM I-745 on the Intestine.

Dig Dis Sci. 2025-1

[5]
Dysphagia in Parkinson Disease: Part II-Current Treatment Options and Insights from Animal Research.

Curr Phys Med Rehabil Rep. 2023-6

[6]
Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.

J Eat Disord. 2024-4-24

[7]
Whole proteome mapping of compound-protein interactions.

Curr Res Chem Biol. 2022

[8]
Dysphagia in Parkinson Disease: Part I - Pathophysiology and Diagnostic Practices.

Curr Phys Med Rehabil Rep. 2023-6

[9]
Pink1-/- Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease.

Dysphagia. 2023-10

[10]
Serotonin system in the human placenta - the knowns and unknowns.

Front Endocrinol (Lausanne). 2022

本文引用的文献

[1]
A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia.

Neurogastroenterol Motil. 2009-6

[2]
The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.

J Int Med Res. 2007

[3]
Exogenous serotonin regulates proliferation of interstitial cells of Cajal in mouse jejunum through 5-HT2B receptors.

Gastroenterology. 2007-9

[4]
5-HT receptors on interstitial cells of Cajal, smooth muscle and enteric nerves.

Neurogastroenterol Motil. 2007-8

[5]
Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.

Gastroenterology. 2007-6

[6]
Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.

J Pharmacol Exp Ther. 2007-9

[7]
Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

Curr Opin Investig Drugs. 2007-5

[8]
Tegaserod inhibits the serotonin transporter SERT.

Digestion. 2007

[9]
Regional differences in expression of TPH-1, SERT, 5-HT(3) and 5-HT(4) receptors in the human stomach and duodenum.

Neurogastroenterol Motil. 2007-5

[10]
Pharmacological characterization of 5-Hydroxytryptamine-receptor subtypes in circular muscle from the rat stomach.

Biol Pharm Bull. 2007-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索